View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. CBDepot
5 May 2021

CBDepot Achieves COSMOS APPROVED Certification for its Isolates

Cannabidiol (CBD) and Cannabigerol (CBG) natural isolates, delivered by CBDepot, are now COSMOS APPROVED cosmetic raw materials by IONC GmbH certifier under the COSMOSstandard.

COSMOS-standard applies to cosmetic products and raw materials intended for use in cosmetic products.

“COSMOS APPROVED certification of both our Cannabidiol and Cannabigerol natural isolates offers to the manufacturers of organic cosmetics the opportunity to include approved cannabinoid ingredients into their formulations. CosIng database lists CBD with anti-sebum, antioxidant, skin conditioning, and skin protecting functions. Now with the recent listing of CBG in CosIng, with skin conditioning function, give the manufacturers two cannabinoids to choose from or combine in their formulas,“ says Jan Storch, production director of CBDepot.

CosIng catalogue is the database created by the European Commission to provide information on cosmetics substances and ingredients. The catalogue has no legal value. However, it serves as a guideline for the Member States and operators.

CBDepot is a pioneer in the manufacture of high-quality natural and synthesized cannabinoids. With roots dating back to 2014, the company has been a leader in helping to establish legal and quality standards for cannabinoid-specific ingredients that have a fast-growing presence in sectors including foods, cosmetics, medical devices, and magistral formulas.

This product originates from cannabis sativa L derivative and is a whitish to yellowish powder.
NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. A weekly roundup of the latest news and analysis, sent every Friday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy


Thank you for subscribing to Pharmaceutical Technology